The Devastating Impact of HIV
Millions of people worldwide are living with HIV, a chronic, life-altering virus that attacks the body's immune system. While significant advancements in treatment have allowed individuals with HIV to live longer lives, the virus can still have a profound impact on a person's physical and mental well-being.
Here are some of the challenges faced by individuals living with HIV:
Weakened Immune System: HIV weakens the immune system, making individuals more susceptible to opportunistic infections and certain cancers.
Chronic Illness Management: Living with HIV often requires lifelong adherence to complex medication regimens, which can come with side effects and can be emotionally and physically demanding.
Stigma and Discrimination: Despite significant progress in education and awareness, stigma and discrimination against people living with HIV persist, creating additional emotional and social burdens.
Invest with Us to Transform HIV Treatment
Get in touch with Barry Wells, MD
The Need for a
Functional Cure
Despite significant progress, HIV remains a global health crisis. Current treatments, while effective, are not accessible to everyone, and long-term use carries costs and challenges. A functional cure could revolutionize HIV care, potentially offering a one-time solution that allows individuals to manage the virus without the need for daily medication.
Addimmune's Approach
Addimmune, is dedicated to developing a functional cure for human immunodeficiency virus (HIV). Addimmune is pioneering AGT103-T, a potentially groundbreaking first-in-class functional cure, and maintains a robust pipeline of diverse gene therapy strategies designed to combat the complexities of the HIV genome. Based in Rockville, MD, Addimmune's team of passionate scientists, physicians, and experts strive to develop a safe and effective approach that modifies a patient's immune cells, enabling them to recognize and eliminate HIV-infected cells, ultimately leading to a cure.
Our Competitive Advantage
Proven Safety & Unexpected Positive Signals
Addimmune, is dedicated to developing a functional cure for human immunodeficiency virus (HIV). Addimmune is pioneering AGT103-T, a potentially groundbreaking first-in-class functional cure, and maintains a robust pipeline of diverse gene therapy strategies designed to combat the complexities of the HIV genome. Based in Rockville, MD, Addimmune's team of passionate scientists, physicians, and experts strive to develop a safe and effective approach that modifies a patient's immune cells, enabling them to recognize and eliminate HIV-infected cells, ultimately leading to a cure.
Analytical Treatment Interruption & Unique Response
We took the bold step of investigating our therapy's impact via an analytical treatment interruption (ATI). To our surprise, we saw a unique immune response across all six participants – increased CD8 cell count after viral rebound and stable CD4 cell count. This suggests AGT103-T may help the immune system build a defense against HIV.
Second ATI & Potential for Improvement
Intrigued by these results, we conducted a second ATI with four participants. We observed consistent immune responses, but even more compellingly, significantly reduced peak viremia and notably lower viral set points. This indicates the immune system may be 'learning' with repeated exposure, potentially leading to even better control with subsequent treatments.
These early clinical results suggest clear competitive advantages:
Safety First: A well-tolerated therapy is crucial for wider adoption.
Unique Responses: We see immune system effects not observed with other HIV gene therapies.
Adaptive Potential: Our data hints at improving viral control over time, positioning AGT103-T as a truly transformative solution.
Experienced, Empathetic & Success Focused
Our leadership team at American Gene Technologies and our HIV division Addimmune, combines decades of experience in immunology, HIV clinical care, and launching groundbreaking medical ventures and businesses. This unique blend of expertise drives our patient-focused approach, guiding us from scientific strategy to clinical design. We've achieved encouraging early clinical results and are strategically positioned for the complex path toward bringing a functional HIV cure to market, with the ultimate goal of creating a future where HIV is a manageable condition, not a life-defining one.
Events
UPCOMING
| Date | Title |
|---|---|
| 04.17.24 | CMO360 |
| 05.07.24 | ASGCT: American Society of Gene & Cell Therapy Conference |
| 05.28.24 | ISCT: International Society for Cell & Gene Therapy Presentation |
| 06.03.24 | BIO International |
| 06.22.24 | IAS: International AIDS Socitety |
| 10.22.24 | ESGCT: European Society of Gene & Cell Therapy |
PAST
| Date | Title |
|---|---|
| 09.26.23 | Cantor Fitzgerald Global Healthcare Conference |
| 10.12.23 | ROTH MKM 2023 Healthcare Opportunities Conference |
| 01.08.24 | J.P. Morgan Healthcare Conference |
| 03.03.24 | CROI: Conference on Retroviruses & Opportunistic Infections |
Contact Us for Investment Opportunities
Reach out to Barry Wells, MD
Accelerating Towards a Functional Cure: Our Development Timeline
We took the bold step of investigating our therapy's impact via an analytical treatment interruption (ATI). To our surprise, we saw a unique immune response across all six participants – increased CD8 cell count after viral rebound and stable CD4 cell count. This suggests AGT103-T may help the immune system build a defense against HIV.
Here is what it means:
Preclinical Success: Robust preclinical data demonstrated safety and potential efficacy
Phase 1a Complete: Initial safety and feasibility established, unexpected positive signals observed.
Analytical Treatment Interruptions: Unique immune responses observed with ATIs.